490 related articles for article (PubMed ID: 33997824)
1. Decay of Fc-dependent antibody functions after mild to moderate COVID-19.
Lee WS; Selva KJ; Davis SK; Wines BD; Reynaldi A; Esterbauer R; Kelly HG; Haycroft ER; Tan HX; Juno JA; Wheatley AK; Hogarth PM; Cromer D; Davenport MP; Chung AW; Kent SJ
Cell Rep Med; 2021 Jun; 2(6):100296. PubMed ID: 33997824
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
[TBL] [Abstract][Full Text] [Related]
3. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
[TBL] [Abstract][Full Text] [Related]
4. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
Beaudoin-Bussières G; Chen Y; Ullah I; Prévost J; Tolbert WD; Symmes K; Ding S; Benlarbi M; Gong SY; Tauzin A; Gasser R; Chatterjee D; Vézina D; Goyette G; Richard J; Zhou F; Stamatatos L; McGuire AT; Charest H; Roger M; Pozharski E; Kumar P; Mothes W; Uchil PD; Pazgier M; Finzi A
Cell Rep; 2022 Feb; 38(7):110368. PubMed ID: 35123652
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.
Shiakolas AR; Kramer KJ; Wrapp D; Richardson SI; Schäfer A; Wall S; Wang N; Janowska K; Pilewski KA; Venkat R; Parks R; Manamela NP; Raju N; Fechter EF; Holt CM; Suryadevara N; Chen RE; Martinez DR; Nargi RS; Sutton RE; Ledgerwood JE; Graham BS; Diamond MS; Haynes BF; Acharya P; Carnahan RH; Crowe JE; Baric RS; Morris L; McLellan JS; Georgiev IS
Cell Rep Med; 2021 Jun; 2(6):100313. PubMed ID: 34056628
[TBL] [Abstract][Full Text] [Related]
6. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
[TBL] [Abstract][Full Text] [Related]
7. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
[TBL] [Abstract][Full Text] [Related]
8. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein.
Hong Y; Guo H; Wei M; Zhang Y; Fang M; Cheng T; Li Z; Ge S; Yao X; Yuan Q; Xia N
J Virol Methods; 2022 Sep; 307():114564. PubMed ID: 35671888
[TBL] [Abstract][Full Text] [Related]
9. A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells.
Beaudoin-Bussières G; Richard J; Prévost J; Goyette G; Finzi A
STAR Protoc; 2021 Dec; 2(4):100851. PubMed ID: 34541555
[TBL] [Abstract][Full Text] [Related]
10. Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2's evasive maneuvering.
Grunst MW; Uchil PD
Cell Rep Med; 2022 Feb; 3(2):100540. PubMed ID: 35233551
[TBL] [Abstract][Full Text] [Related]
11. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
[TBL] [Abstract][Full Text] [Related]
12. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
13. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Richardson SI; Manamela NP; Motsoeneng BM; Kaldine H; Ayres F; Makhado Z; Mennen M; Skelem S; Williams N; Sullivan NJ; Misasi J; Gray GG; Bekker LG; Ueckermann V; Rossouw TM; Boswell MT; Ntusi NAB; Burgers WA; Moore PL
Cell Rep Med; 2022 Feb; 3(2):100510. PubMed ID: 35233544
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Dufloo J; Grzelak L; Staropoli I; Madec Y; Tondeur L; Anna F; Pelleau S; Wiedemann A; Planchais C; Buchrieser J; Robinot R; Ungeheuer MN; Mouquet H; Charneau P; White M; Lévy Y; Hoen B; Fontanet A; Schwartz O; Bruel T
Cell Rep Med; 2021 May; 2(5):100275. PubMed ID: 33899033
[TBL] [Abstract][Full Text] [Related]
16. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
Chen X; Rostad CA; Anderson LJ; Sun HY; Lapp SA; Stephens K; Hussaini L; Gibson T; Rouphael N; Anderson EJ
Virology; 2021 Jul; 559():1-9. PubMed ID: 33774551
[TBL] [Abstract][Full Text] [Related]
17. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
18. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
19. Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence.
Fuentes-Villalobos F; Garrido JL; Medina MA; Zambrano N; Ross N; Bravo F; Gaete-Argel A; Oyarzún-Arrau A; Amanat F; Soto-Rifo R; Valiente-Echeverría F; Ocampo R; Esveile C; Ferreira L; Cabrera J; Torres V; Rioseco ML; Riquelme R; Barría S; Alvarez R; Pinos Y; Krammer F; Calvo M; Barria MI;
Front Immunol; 2022; 13():796481. PubMed ID: 35197972
[TBL] [Abstract][Full Text] [Related]
20. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
Atyeo C; Slein MD; Fischinger S; Burke J; Schäfer A; Leist SR; Kuzmina NA; Mire C; Honko A; Johnson R; Storm N; Bernett M; Tong P; Zuo T; Lin J; Zuiani A; Linde C; Suscovich T; Wesemann DR; Griffiths A; Desjarlais JR; Juelg BD; Goudsmit J; Bukreyev A; Baric R; Alter G
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
